Construction of an Immunity and Ferroptosis-Related Risk Score Model to Predict Ovarian Cancer Clinical Outcomes and Immune Microenvironment

被引:5
作者
Wei, Chunyan [1 ]
Zhao, Gang [1 ]
Gao, Mei [1 ]
Liu, Yunting [2 ]
Lei, Pan [1 ]
Cao, Ting [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gynaecol & Obstet, Xian 710004, Shaanxi, Peoples R China
[2] Shangluo Cent Hosp, Dept Gynaecol & Obstet, Shangluo 726000, Shaanxi, Peoples R China
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2023年 / 28卷 / 01期
关键词
immunity; ferroptosis; ovarian cancer; signature genes; prognosis; tumor immune microenvironment; immune checkpoint; immunotherapy; GRANZYME-B; THERAPEUTIC TARGET; MUTATION BURDEN; CELLS; SURVIVAL; GENES; PROPORTION; SIGNATURE; CARCINOMA; PATHWAY;
D O I
10.31083/j.fbl2801004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Ovarian cancer (OV) is a severe and common gynecological disease. Ferroptosis can regulate the progression and invasion of tumors. The immune system is a decisive factor in cancer. The present study aimed to use gene expression data to establish an immunity and ferroptosis-related risk score model as a prognostic biomarker to predict clinical outcomes and the immune microenvironment of OV. Methods: Common gene expression data were searched from the Gene Expression Omnibus and The Cancer Genome Atlas databases. Immunity-related genes and ferroptosis-related genes were searched and downloaded from the ImmPort and FerrDb databases, followed by the analysis of the overall survival of patients with OV and the identification of genes. Subsequently, the status of the infiltration of immune cells and the association between immune checkpoints and risk score were assessed. Results: A total of 10 prognostic genes (C5AR1, GZMB, IGF2R, ISG20, PPP3CA, STAT1, TRIM27, TSHR, RB1, and EGFR) were included in the immunity and ferroptosis-related risk score model. The high-risk group had a higher infiltration of immune cells. The risk score, an independent prognostic feature of OV was negatively associated with each immune checkpoint. The risk score may thus help to predict the response to immunotherapy. Conclusions: The immunity and ferroptosis-related risk score model is an independent prognostic factor for OV. The established risk score may help to predict the response of patients to immunotherapy.
引用
收藏
页数:14
相关论文
共 60 条
[1]   From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer [J].
Angel, Helen ;
Galon, Jerome .
CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) :261-267
[2]   Novel gene signatures for prognosis prediction in ovarian cancer [J].
Bao, Mingyang ;
Zhang, Lihua ;
Hu, Yueqing .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (17) :9972-9984
[3]   Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].
Barbie, David A. ;
Tamayo, Pablo ;
Boehm, Jesse S. ;
Kim, So Young ;
Moody, Susan E. ;
Dunn, Ian F. ;
Schinzel, Anna C. ;
Sandy, Peter ;
Meylan, Etienne ;
Scholl, Claudia ;
Froehling, Stefan ;
Chan, Edmond M. ;
Sos, Martin L. ;
Michel, Kathrin ;
Mermel, Craig ;
Silver, Serena J. ;
Weir, Barbara A. ;
Reiling, Jan H. ;
Sheng, Qing ;
Gupta, Piyush B. ;
Wadlow, Raymond C. ;
Le, Hanh ;
Hoersch, Sebastian ;
Wittner, Ben S. ;
Ramaswamy, Sridhar ;
Livingston, David M. ;
Sabatini, David M. ;
Meyerson, Matthew ;
Thomas, Roman K. ;
Lander, Eric S. ;
Mesirov, Jill P. ;
Root, David E. ;
Gilliland, D. Gary ;
Jacks, Tyler ;
Hahn, William C. .
NATURE, 2009, 462 (7269) :108-U122
[4]   Iron addiction: a novel therapeutic target in ovarian cancer [J].
Basuli, D. ;
Tesfay, L. ;
Deng, Z. ;
Paul, B. ;
Yamamoto, Y. ;
Ning, G. ;
Xian, W. ;
McKeon, F. ;
Lynch, M. ;
Crum, C. P. ;
Hegde, P. ;
Brewer, M. ;
Wang, X. ;
Miller, L. D. ;
Dyment, N. ;
Torti, F. M. ;
Torti, S. V. .
ONCOGENE, 2017, 36 (29) :4089-4099
[5]   Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations [J].
Birkbak, Nicolai Juul ;
Kochupurakkal, Bose ;
Izarzugaza, Jose M. G. ;
Eklund, Aron C. ;
Li, Yang ;
Liu, Joyce ;
Szallasi, Zoltan ;
Matulonis, Ursula A. ;
Richardson, Andrea L. ;
Iglehart, J. Dirk ;
Wang, Zhigang C. .
PLOS ONE, 2013, 8 (11)
[6]  
Boyd LR, 2018, ONCOLOGY-NY, V32, P418
[7]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[8]   Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].
Chan, T. A. ;
Yarchoan, M. ;
Jaffee, E. ;
Swanton, C. ;
Quezada, S. A. ;
Stenzinger, A. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56
[9]   Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade [J].
Charoentong, Pornpimol ;
Finotello, Francesca ;
Angelova, Mihaela ;
Mayer, Clemens ;
Efremova, Mirjana ;
Rieder, Dietmar ;
Hackl, Hubert ;
Trajanoski, Zlatko .
CELL REPORTS, 2017, 18 (01) :248-262
[10]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330